Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DoximityDOCS +4.45%86 3-Year Revenue Growth Rate is 18.20% as of Jun. 2026, which is 29% below its 10-year median of 25.80. GuruFocus rates DOCS with a GF Score™ of 86/100 and a GF Value™ of $45.52 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 612 Healthcare Providers & Services companies, Doximity ranks better than 79.08% on this metric.
During the past 12 months, Doximity's average Revenue per Share Growth Rate was 14.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 18.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 21.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
During the past 8 years, the highest 3-Year average Revenue per Share Growth Rate of Doximity was 53.20% per year. The lowest was 16.40% per year. And the median was 25.80% per year.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
Doximity 3-Year Revenue Growth Rate Related Terms
DOCS vs PRVA, WAY, HTFL: 3-Year Revenue Growth Rate Comparison
For the Health Information Services subindustry, Doximity's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Doximity 3-Year Revenue Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Doximity's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where Doximity's 3-Year Revenue Growth Rate falls into.
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
What does a 3-Year Revenue Growth Rate of 18.20% mean?
Doximity (DOCS) has a 3-Year Revenue Growth Rate of 18.20% as of Jun. 2026. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Doximity and its competitors. This is 29% below median its historical median of 25.80. Over the past decade, Doximity's 3-Year Revenue Growth Rate has ranged from 16.40 to 53.20. According to the industry distribution chart, Doximity ranks #128 out of 612 companies in the Healthcare Providers & Services industry, placing it in the top 20.9%.
Is Doximity's 3-Year Revenue Growth Rate too high?
Doximity's current 3-Year Revenue Growth Rate of 18.20% is 29% below median its 10-year median of 25.80. Over the past 10 years, this metric has ranged from a low of 16.40 to a high of 53.20. The Healthcare Providers & Services industry median 3-Year Revenue Growth Rate is 6.90. Doximity's value of 18.20% is 163.8% above this industry median. Based on the distribution chart, Doximity ranks #128 out of 612 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Doximity has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Doximity's 3-Year Revenue Growth Rate compare to PRVA and WAY?
According to the Healthcare Providers & Services industry distribution chart, Doximity ranks #128 out of 612 companies for 3-Year Revenue Growth Rate. This places Doximity in the top 21% of its industry — outperforming the majority of peers. The industry median 3-Year Revenue Growth Rate is 6.90. Doximity's value of 18.20% is 163.8% above this benchmark. Historically, Doximity's own 3-Year Revenue Growth Rate has ranged from 16.40 to 53.20 over the past decade. While the company's 10-year median is 25.80 vs. the industry median of 6.90, Doximity has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Revenue Growth Rate for a Healthcare Providers & Services company?
The median 3-Year Revenue Growth Rate among Healthcare Providers & Services companies is 6.90, based on 612 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Revenue Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Revenue Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Doximity's current 3-Year Revenue Growth Rate of 18.20% is 163.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Revenue Growth Rate mean?
A high 3-Year Revenue Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Doximity and its competitors. For the Healthcare Providers & Services industry, the median 3-Year Revenue Growth Rate is 6.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Doximity's current 3-Year Revenue Growth Rate is 18.20%, which is 29% below median its own 10-year median of 25.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Doximity stock overvalued right now?
Based on GuruFocus' analysis, Doximity (DOCS) is currently considered Significantly Undervalued. The stock's GF Value™ is $45.52, compared to a current price of $26.73 — trading 41.3% below its estimated fair value. The current 3-Year Revenue Growth Rate is 18.20%, which is 29% below median its 10-year median of 25.80 and 163.8% above the Healthcare Providers & Services industry median of 6.90. Doximity's overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Revenue Growth Rate calculated?
3-Year Revenue Growth Rate is calculated from a company's financial statements. For Doximity (DOCS), the current 3-Year Revenue Growth Rate is 18.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Doximity (DOCS) Overvalued in 2026?
Based on GuruFocus' analysis, Doximity stock appears to be undervalued.
The current stock price of $26.73 is trading 41.3% below its estimated GF Value™ of $45.52.
GuruFocus considers Doximity to be Significantly Undervalued.
Key valuation signals for DOCS:
3-Year Revenue Growth Rate: 18.20% (29% below median its 10-year median of 25.80)
GF Value™: $45.52 vs. price of $26.73 (41.3% below fair value)
Industry Position: 163.8% above the Healthcare Providers & Services median (#128 of 612)
No single metric tells the full story. See the DOCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Doximity Inc provides an online platform, which enables physicians and other healthcare professionals to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. The Company's customers include pharmaceutical companies and health systems that connect with healthcare professionals through the Company's digital Marketing, Hiring, and Workflow Solutions. Marketing Solutions provide customers with the ability to share tailored content on the network. Hiring Solutions enable customers to identify, connect with, and hire from the network of both active and passive potential medical professional candidates.
86GF Score
Get the complete analysis for DOCS
3-Year Revenue Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DOCS has been successfully added to your 
